STAT1 acts as a tumor promoter for leukemia development.

[1]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[2]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[3]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[4]  E. Wagner,et al.  Stat5 tetramer formation is associated with leukemogenesis. , 2005, Cancer cell.

[5]  M. Artwohl,et al.  TYK2 is a key regulator of the surveillance of B lymphoid tumors. , 2004, The Journal of clinical investigation.

[6]  T. Yoshimoto,et al.  An Indispensable Role for STAT1 in IL-27-Induced T-bet Expression but Not Proliferation of Naive CD4+ T Cells1 , 2004, The Journal of Immunology.

[7]  Jonathan M Irish,et al.  Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells , 2004, Cell.

[8]  J. Spivak.  The chronic myeloproliferative disorders: clonality and clinical heterogeneity. , 2004, Seminars in hematology.

[9]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[10]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[11]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[12]  M. David,et al.  Impaired Development of CD4+ CD25+ Regulatory T Cells in the Absence of STAT1 , 2004, The Journal of experimental medicine.

[13]  C. Hunter,et al.  STAT1 Plays a Critical Role in the Regulation of Antimicrobial Effector Mechanisms, but Not in the Development of Th1-Type Responses during Toxoplasmosis1 , 2004, The Journal of Immunology.

[14]  G. Lesinski,et al.  The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. , 2004, The Journal of surgical research.

[15]  U. Koszinowski,et al.  Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses , 2003 .

[16]  F. Garrido,et al.  MHC class I‐deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components , 2003, International journal of cancer.

[17]  G. Lesinski,et al.  The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse , 2003 .

[18]  J. Ihle,et al.  Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. , 2003, Blood.

[19]  M. Caligiuri,et al.  What does it take to make a natural killer? , 2003, Nature Reviews Immunology.

[20]  Sam J. P. Gobin,et al.  Regulation of human β2-microglobulin transactivation in hematopoietic cells , 2003 .

[21]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[22]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[23]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[24]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[25]  Lloyd J. Old,et al.  The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .

[26]  G. Stark,et al.  Stat1-Dependent, p53-Independent Expression of p21waf1 Modulates Oxysterol-Induced Apoptosis , 2002, Molecular and Cellular Biology.

[27]  Adelheid Cerwenka,et al.  Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.

[28]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[29]  David E. Levy,et al.  Distinct Requirements for IFNs and STAT1 in NK Cell Function1 , 2000, The Journal of Immunology.

[30]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[31]  O. Bernard,et al.  TEL-JAK2 transgenic mice develop T-cell leukemia. , 2000, Blood.

[32]  T. Mcclanahan,et al.  Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. , 2000, Immunity.

[33]  J. Darnell,et al.  The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.

[34]  David E. Levy,et al.  STAT1 Affects Lymphocyte Survival and Proliferation Partially Independent of Its Role Downstream of IFN-γ1 , 2000, The Journal of Immunology.

[35]  R. Foà,et al.  Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. , 2000, The hematology journal : the official journal of the European Haematology Association.

[36]  D. Levy,et al.  Differential Regulation of Constitutive Major Histocompatibility Complex Class I Expression in T and B Lymphocytes , 1999, The Journal of experimental medicine.

[37]  F. Fallarino,et al.  Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. , 1999, Journal of immunology.

[38]  J. D. Di Santo,et al.  Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor γ chain , 1998 .

[39]  J. Aster,et al.  Transformation of hematopoietic cell lines to growth‐factor independence and induction of a fatal myelo‐ and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes , 1998, The EMBO journal.

[40]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[41]  L. Platanias,et al.  Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. , 1998, Blood.

[42]  R Berger,et al.  A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.

[43]  P. Marynen,et al.  Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.

[44]  P. Halloran,et al.  IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. , 1997, Journal of immunology.

[45]  D. Levy,et al.  Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease , 1996, Cell.

[46]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[47]  A. Bradley,et al.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.

[48]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[49]  B. Ozanne,et al.  Multistage progression of Abelson virus-infected murine pre-B-cells to the tumorigenic state. , 1990, Cancer research.

[50]  N. Rosenberg,et al.  The viral and cellular forms of the Abelson (abl) oncogene. , 1988, Advances in virus research.

[51]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[52]  W. On.  Functions of the abl oncogene. , 1986 .

[53]  H. Abelson,et al.  Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice. , 1970, Cancer research.